Publication date: Jan 20, 2025

High-accuracy diagnostic screening tests for Mycobacterium tuberculosis (MTB) infection are required, primarily to detect patients with latent infections (LTBIs) in order to avoid their progression to active tuberculosis disease. The performance of the novel IGRA LIOFeron(R)TB/LTBI was evaluated in children. The originality of this test is the new MTB antigen contained (L-alanine dehydrogenase), identified as a tool to differentiate active TB from LTBI infection. From March 2022 to November 2023, a population of 90 children was enrolled and grouped into healthy, active TB or LTBI individuals, based on diagnostic guidelines. The blood of all these participants was tested with LIOFeron(R)TB/LTBI assay in comparison to diagnosis, as gold standard, and to the current used IGRA QuantiFERON(R)-TB Gold Plus. The two assays demonstrated an excellent concordance of their results with patients’ diagnosis of MTB infection. The performance of LIOFeron(R)TB/LTBI assay in terms of accuracy of MTB infection diagnosis was high at ROC analysis (AUC = 0. 997), and the test showed 100% sensitivity in LTBI detection. The QuantiFERON(R)-TB Gold Plus sensitivity for LTBI detection was 85. 7%. Based on the obtained results, the LIOFeron(R)TB/LTBI assay appears to be a promising test for TB and LTBI screening among paediatric patients. • The detection of LTBI in children, exposed to MTB infections, followed by appropriate treatment, has a pivotal role in reducing tuberculosis burden. • IGRA tests are easy-to-use methods for helping large TB screening in paediatrics. • The LIOFeron(R)TB/LTBI performance evaluation showed 100% of sensitivity in the detection of LTBI patients. • The LIOFeron(R)TB/LTBI assay might be useful for the detection of LTBI and active tuberculosis paediatric patients.

Semantics

Original Article